The RATinG (Risk Adapted Therapy in Acute GvHD) is the first trial to explore granulocyte-macrophage colony-stimulating factor (GM-CSF) neutralization for the early treatment of participants with high-risk...
Of the 14 participants enrolled and treated with lenzilumab plus azacitidine, ten are evaluable with three to eighteen months of follow-up and all ten have had a rapid clinical response Building upon previously...
CMML is an aggressive, poorly understood cancer; approximately 20% of patients survive three years from diagnosisEleven subjects dosed with lenzilumab and with current standard of care, azacitidineSix...
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Humanigen, Inc. (“Humanigen” or “the Company”) (NASDAQ: HGEN) and...
/PRNewswire/ -- The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN) alleging...
/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Humanigen, Inc. (NASDAQ: HGEN) between May 16,...
/PRNewswire/ -- Attention Humanigen, Inc. ("Humanigen") (NASDAQ: HGEN) shareholders: The Law Offices of Vincent Wong announce that a class action lawsuit has...
/PRNewswire/ -- Jakubowitz Law announces that a securities fraud class action lawsuit has commenced on behalf of shareholders of Humanigen, Inc. (NASDAQ: HGEN)....
/PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) of a class action securities lawsuit....
/PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Humanigen, Inc. ("Humanigen" or the "Company") (NASDAQ: HGEN) and...